Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

Inclusion Criteria:

• histologically confirmed nasopharyngeal cancer
• chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment)
• ECOG 0-1
• at least one measurable lesion

Exclusion Criteria:

• other cancer
• pregnat
• docetaxel hypersentitivity history
• severe heart or pulmonary disease